Table 1.
Characteristics of patients with cGVHD 2 years after rituximab
| Stable/improved (n = 11) | Unresponsive (n = 9) | P | |
|---|---|---|---|
| Age, y (range) | 39 (20-61) | 41 (30-58) | .45 |
| Sex | |||
| Female | 5 (45) | 5 (56) | > .99 |
| Male | 6 (55) | 4 (44) | |
| Disease | |||
| ALL | 0 (0) | 1 (11) | |
| AML | 3 (27) | 3 (33) | |
| CLL | 1 (9) | 0 (0) | |
| CML | 4 (36) | 4 (44) | |
| MDS | 3 (27) | 0 (0) | |
| NHL | 0 (0) | 1 (11) | |
| Type of transplant | |||
| RIC | 2 (18) | 3 (33) | .62 |
| STD | 9 (82) | 6 (67) | |
| Cell source | |||
| BM | 3 (27) | 3 (33) | > .99 |
| PBSC | 8 (73) | 6 (67) | |
| T cell-depleted | 3 (27) | 3 (33) | > .99 |
| Non–T cell-depleted | 8 (73) | 6 (67) | |
| No. of rituximab doses | |||
| 4 | 2 (18) | 3 (33) | .44 |
| 6 | 0 (0) | 1 (11) | |
| 8 | 9 (82) | 5 (56) | |
| Steroids | |||
| < 30 mg | 11 (100) | 6 (67) | .07 |
| ≥ 30 mg | 0 (0) | 3 (33) | |
| Thalidomide | 0 (0) | 1 (11) | .45 |
| Sirolimus | 4 (36) | 4 (44) | .17 |
| Tacrolimus | 4 (36) | 3 (33) | .26 |
| MMF | 0 (0) | 3 (33) | .07 |
| ECP | 2 (18) | 4 (44) | .34 |
| Grade II-IV aGVHD | 5 (45) | 2 (22) | .37 |
| Time from post-HSCT to onset of cGVHD (range) | 9.5 (6-60) | 10.0 (4-39) | .97 |
| Time from post-HSCT to date of sample (range) | 10.0 (4-39) | 9.0 (6-60) | .91 |
| cGVHD type | |||
| Sclerodermatous | 5 (45) | 8 (89) | .07 |
| Lichenoid | 1 (9) | 2 (22) | .57 |
| Mouth | 3 (27) | 5 (56) | .36 |
| Lung | 1 (9) | 0 (0) | > .99 |
| Liver | 5 (45) | 2 (22) | .37 |
| Marrow | 1 (9) | 0 (0) | > .99 |
| Muscle | 3 (27) | 0 (0) | .22 |
| Eye | 2 (18) | 1 (11) | > .99 |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; RIC, reduced-intensity conditioning; STD, standard; BM, bone marrow; PBSC, peripheral blood stem cell; MMF, mycophenolate mofetil; and ECP, extracorporeal photopheresis.